1. Home
  2. VKTX vs CCOI Comparison

VKTX vs CCOI Comparison

Compare VKTX & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • CCOI
  • Stock Information
  • Founded
  • VKTX 2012
  • CCOI 1999
  • Country
  • VKTX United States
  • CCOI United States
  • Employees
  • VKTX N/A
  • CCOI N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • CCOI Telecommunications Equipment
  • Sector
  • VKTX Health Care
  • CCOI Consumer Discretionary
  • Exchange
  • VKTX Nasdaq
  • CCOI Nasdaq
  • Market Cap
  • VKTX 4.7B
  • CCOI 3.8B
  • IPO Year
  • VKTX 2015
  • CCOI N/A
  • Fundamental
  • Price
  • VKTX $32.87
  • CCOI $73.57
  • Analyst Decision
  • VKTX Strong Buy
  • CCOI Buy
  • Analyst Count
  • VKTX 12
  • CCOI 11
  • Target Price
  • VKTX $106.75
  • CCOI $82.00
  • AVG Volume (30 Days)
  • VKTX 3.5M
  • CCOI 425.3K
  • Earning Date
  • VKTX 02-05-2025
  • CCOI 02-27-2025
  • Dividend Yield
  • VKTX N/A
  • CCOI 5.43%
  • EPS Growth
  • VKTX N/A
  • CCOI N/A
  • EPS
  • VKTX N/A
  • CCOI 0.82
  • Revenue
  • VKTX N/A
  • CCOI $976,013,000.00
  • Revenue This Year
  • VKTX N/A
  • CCOI $19.45
  • Revenue Next Year
  • VKTX N/A
  • CCOI $3.48
  • P/E Ratio
  • VKTX N/A
  • CCOI $89.53
  • Revenue Growth
  • VKTX N/A
  • CCOI 24.03
  • 52 Week Low
  • VKTX $20.92
  • CCOI $50.80
  • 52 Week High
  • VKTX $99.41
  • CCOI $86.76
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 26.61
  • CCOI 44.35
  • Support Level
  • VKTX $32.51
  • CCOI $72.06
  • Resistance Level
  • VKTX $43.55
  • CCOI $73.78
  • Average True Range (ATR)
  • VKTX 2.15
  • CCOI 2.11
  • MACD
  • VKTX -0.41
  • CCOI 0.02
  • Stochastic Oscillator
  • VKTX 17.78
  • CCOI 31.80

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About CCOI Cogent Communications Holdings Inc.

Cogent carries over one fifth of the world's internet traffic over its network and is a broadband provider for businesses. Cogent's corporate customers are in high-rise office buildings; the firm provides them with two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for over half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.

Share on Social Networks: